How we treat HCM
If you are diagnosed with HCM, your doctor may recommend periodic monitoring, medication or surgery based on your symptoms. Your care team may include cardiologists, cardiac surgeons, heart specialists and technicians working together to create a personalized care plan that’s right for you.
- An alcohol septal ablation is used to make the walls of the heart muscle thinner so your heart can pump better
- A mitral valve repair or replacement for damaged or diseased mitral valve to help improve blood flow
- Implantation of a cardioverter-defibrillator (ICD) to help maintain a normal heart rate and support bloodflow
- Medications, including advanced therapies such as Camzyos® (mavacamten) and Myqorzo™ (aficamten), to help relieve chest pain, shortness of breath, and regulate irregular heartbeat
- Surgery to remove parts of the heart muscle if medications are not effective
How we treat cardiac amyloidosis
Treatment depends on the type of amyloid identified. Goals are to manage heart failure symptoms, prevent complications from abnormal heart rhythms, and slow down or stop the progression of the amyloid deposits.
- For ATTR-CM: Treatments aim to stabilize the TTR protein or reduce the liver's production of the protein
- For AL Amyloidosis: Treatment focuses on suppressing the production of the light chain protein, often through chemotherapy or immunotherapy.
- In advanced cases, or for certain types of hereditary ATTR, a heart or liver transplant may be considered.
We also have clinical research trials available for ATTR to hopefully further improve the treatment options.
Clinical trials
Our doctors are committed to being leaders in cardiovascular research, working to help improve how we diagnose and treat heart and vascular diseases. You can talk to your cardiologist if you are interested in participating in clinical trials.
ACACIA
Phase 3 trial to evaluate the efficacy and safety of Aficamten compared to placebo in adults with symptomatic HCM
Discover HCM
A prospective registry study to assess real-world patient characteristics, treatment patterns, and longitudinal outcomes in patients receiving Mavacamten and other treatments for symptomatic obstructive hypertrophic cardiomyopathy
MAPLE
Phase 3 trial to evaluate the efficacy and safety of Aficamten compared to Metoprolol succinate in adults with symptomatic HCM